- Trials with a EudraCT protocol (15)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
15 result(s) found for: Isoleucine.
Displaying page 1 of 1.
EudraCT Number: 2021-002329-56 | Sponsor Protocol Number: FISIO | Start Date*: 2021-10-19 | |||||||||||
Sponsor Name:Sociedad Española de Medicina Intensiva, Crítica y Unidades Coronarias (SEMICYUC) | |||||||||||||
Full Title: Exploratory study to evaluate the efficacy and safety of nutritionally administering 1.5 g protein/kg/day vs. 1.0 g protein/kg/day in the catabolic phase of the critically ill patient on mechanical... | |||||||||||||
Medical condition: Acquired Weakness in the Intensive Care Unit (DAUCI) of the critically ill patient. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2009-012602-39 | Sponsor Protocol Number: 05-NEOV-002 | Start Date*: 2010-05-17 | |||||||||||
Sponsor Name:Fresenius Kabi Deutschland GmbH | |||||||||||||
Full Title: A randomised, double-blind study evaluating the safety, tolerability, protein accretion, amino acid plasma levels and long-term outcome of Neoven compared to Vaminolact(R) in premature very low bir... | |||||||||||||
Medical condition: The product is aimed to be used where parenteral nutrition is required. The intended indication is: Supply of essential and non-essential amino acids as part of parenteral nutrition for premature ... | |||||||||||||
|
|||||||||||||
Population Age: Preterm newborn infants, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) NL (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-012604-92 | Sponsor Protocol Number: 05-NEOV-004 | Start Date*: 2010-04-19 | |||||||||||
Sponsor Name:Fresenius Kabi Deutschland GmbH | |||||||||||||
Full Title: A randomised, double-blind study of the safety and efficacy of Neoven compared to Vaminolact in infants and children requiring long-term parenteral nutrition | |||||||||||||
Medical condition: The product is aimed to be used where parenteral nutrition is required. The intended indication is: Supply of essential and non-essential amino acids as part of Parenteral Nutrition for infants an... | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-012603-26 | Sponsor Protocol Number: 05-NEOV-003 | Start Date*: 2010-04-08 | |||||||||||
Sponsor Name:Fresenius Kabi Deutschland GmbH [...] | |||||||||||||
Full Title: A randomised, double-blind study evaluating the safety, tolerability and clinical outcome of Neoven compared to Vaminolact in premature ELBW infants | |||||||||||||
Medical condition: The product is aimed to be used where parenteral nutrition is required. The intended indication is: Supply of essential and non-essential amino acids as part of Parenteral Nutrition for premature ... | |||||||||||||
|
|||||||||||||
Population Age: Preterm newborn infants, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) DE (Prematurely Ended) FR (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-000429-20 | Sponsor Protocol Number: 05-NEOV-001 | Start Date*: 2008-10-17 | |||||||||||
Sponsor Name:Fresenius Kabi Deutschland GmbH | |||||||||||||
Full Title: A randomised, double-blind study evaluating the safety, tolerability, and amino acid plasma levels of Neoven compared to Vaminolact in infants after surgical interventions. | |||||||||||||
Medical condition: The product is aimed to be used where parenteral nutrition is required. The indended indication is: Supply of essential and non-essential amino acids as part of parenteral nutrition for preterm an... | |||||||||||||
|
|||||||||||||
Population Age: Preterm newborn infants, Newborns, Infants and toddlers, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Completed) BE (Completed) DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-002264-33 | Sponsor Protocol Number: AH01 | Start Date*: 2014-08-25 | |||||||||||
Sponsor Name:Ole Hamberg | |||||||||||||
Full Title: Rifaximin in alcoholic hepatitis: effects on inflammatory and metabolic markers. | |||||||||||||
Medical condition: Alcoholic hepatitis. | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2007-006153-31 | Sponsor Protocol Number: CSC/P01/07/Mu.F | Start Date*: 2008-04-23 | |||||||||||
Sponsor Name:Baxter R and D Europe SCRL | |||||||||||||
Full Title: Safety and efficacy of subcutaneous (SC) administration of Clinimix N9G15E in elderly patients at risk for malnutrition, at a dose of 1 liter infused over 12 hours for 7 to 10 consecutive days. A p... | |||||||||||||
Medical condition: The population studied will be the elderly population at risk for malnutrition without any predefined pathology at hospital geriatrician wards. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-005325-39 | Sponsor Protocol Number: ELX-NPP-2016-01 | Start Date*: 2016-04-26 | |||||||||||
Sponsor Name:Dr. Antonio Arroyo Sebastián | |||||||||||||
Full Title: A RANDOMIZED, CONTROLLED, CLINICAL TRIAL TO COMPARE PERIPHERAL PARENTERAL NUTRITION (PeriOlimel N4-E) VS CONVENTIONAL FLUID THERAPY IN ENHANCED RECOVERY AFTER SURGERY (ERAS) PROTOCOL IN COLORECTAL ... | |||||||||||||
Medical condition: Cancer colorectal | |||||||||||||
|
|||||||||||||
Population Age: Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2009-009918-40 | Sponsor Protocol Number: LG-TAU-2008-04 | Start Date*: 2009-07-22 | |||||||||||
Sponsor Name:LABORATORIOS GRIFOLS, S.A. | |||||||||||||
Full Title: Ensayo Clínico fase IV, prospectivo, aleatorizado, doble ciego, de grupos paralelos y unicéntrico, para evaluar el efecto de la taurina en Nutrición Parenteral Total sobre la función hepática en pa... | |||||||||||||
Medical condition: Evaluar el efecto de la taurina en nutrición Parenteral Total sobre la función hepática en pacientes postquirúrgicos. Evaluate the effect of taurine in Total Parenteral Nutrition on the hepatic fun... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-004946-41 | Sponsor Protocol Number: SP-PP18 | Start Date*: 2019-09-12 |
Sponsor Name:Dr. Virgilio P. Carnielli, | ||
Full Title: Personalized versus standard parenteral nutrition for preterm infants with a birth weight greater than 1250 grams: a phase IV randomized clinical trial | ||
Medical condition: Growth of preterm infants with a birth weight greater than 1250g on parenteral nutrition. | ||
Disease: | ||
Population Age: Preterm newborn infants, Under 18 | Gender: Male, Female | |
Trial protocol: ES (Ongoing) IT (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2008-005242-23 | Sponsor Protocol Number: NV-NEGRIN-2008-001 | Start Date*: 2009-03-31 |
Sponsor Name:Nicanor Vega Diaz. Hospital Universitario de Gran Canaria Dr Negrin | ||
Full Title: ESTUDIO UNICENTRICO, PROSPECTIVO Y ALEATORIZADO DE COMPARACION DE LOS EFECTOS DE DIFERENTES SOLUCIONES DE DIALISIS PERITONEAL SOBRE LA FUNCIONALIDAD DE LA MEMBRANA PERITONEAL EN PACIENTES INCIDE... | ||
Medical condition: Cambios funcionales de la membrana peritoneal en los pacientes en diálisis peritoneal automatizada que sean asignado a dianeal o physioneal | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Restarted) | ||
Trial results: (No results available) |
EudraCT Number: 2020-005969-13 | Sponsor Protocol Number: AXA1665-101 | Start Date*: 2021-08-11 | ||||||||||||||||
Sponsor Name:Axcella Health, Inc. | ||||||||||||||||||
Full Title: A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of AXA1665 in Subjects With Liver Cirrhosis and Prior Overt Hepatic Encephalopathy (EM... | ||||||||||||||||||
Medical condition: Overt Hepatic Encephalopathy in Subjects with Liver Cirrhosis | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: ES (Completed) PL (Completed) HU (Prematurely Ended) IT (Prematurely Ended) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-000685-15 | Sponsor Protocol Number: AXA1125-101 | Start Date*: 2021-10-18 | |||||||||||
Sponsor Name:Axcella Health, Inc. | |||||||||||||
Full Title: A Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study to Evaluate the Safety, Tolerability, and Efficacy of AXA1125 in Subjects With Non Cirrhotic, Non Alcoholic Steatohepatitis and Fi... | |||||||||||||
Medical condition: Noncirrhotic, Nonalcoholic Steatohepatitis and Fibrosis | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: PL (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2009-009995-11 | Sponsor Protocol Number: CNIM811B2202 | Start Date*: 2009-07-20 | |||||||||||
Sponsor Name:Novartis Pharma Services AG | |||||||||||||
Full Title: A randomized, adaptive-design dose finding study to assess the antiviral efficacy and safety of NIM811 administered in combination with Standard of Care (SOC) for 12 weeks in relapsed HCV-1 infecte... | |||||||||||||
Medical condition: Hepatitis C genotype 1 relapser | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) ES (Completed) IT (Completed) BE (Completed) NL (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-001394-29 | Sponsor Protocol Number: 31998 | Start Date*: 2007-12-28 | |||||||||||
Sponsor Name:Baxter Healthcare Corporation | |||||||||||||
Full Title: Multi-center, prospective trial to demonstrate Improved Metabolic control of PPEN vs DDDD in DIAbetic CAPD patients -The IMPENDIA Trial | |||||||||||||
Medical condition: End stage renal disease patients with Diabetes Type I and II on Continuous Ambulatory Peritoneal Dialysis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) PT (Prematurely Ended) AT (Completed) IT (Prematurely Ended) CZ (Completed) ES (Prematurely Ended) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
